Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations

Journal of Clinical Oncology

Volumn 31, Issue 25, 2013, Pages 3162-3164

  Bhatt, Vijaya R ^a   Kedia, Shiksha ^b   Kessinger, Anne ^a   Ganti, Apar K ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c Nebraska Western Iowa Veterans Affairs Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; GEFITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

BRAIN METASTASIS; CANCER RECURRENCE; GENE DOSAGE; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ARTICLE; BRAIN RADIATION; CAUCASIAN; ETHNIC DIFFERENCE; GENE AMPLIFICATION; GENE MUTATION; HISTOLOGY; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); SEX DIFFERENCE; SMOKING; BRAIN TUMOR; DRUG ANTAGONISM; FEMALE; GENETICS; LUNG TUMOR; MALE; METASTASIS; NOTE; PATHOLOGY; SKULL IRRADIATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CRANIAL IRRADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84886489677     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8915     Document Type: Letter

References (19)

1. Welsh JW, Komaki R, Amini A, et al: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31:895-902, 2013
2. Hirsch FR, Bunn PA Jr: EGFR testing in lung cancer is ready for prime time. Lancet Oncol 10:432-433, 2009
3. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
4. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24:1700-1704, 2006 (Pubitemid 46622141)
5. Lee HL, Chung TS, Ting LL, et al: EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 30:181, 2012
6. Sekine A, Kato T, Hagiwara E, et al: Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 77:64-69, 2012
7. Porta R, Sánchez-Torres JM, Paz-Ares L, et al: Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation. Eur Respir J 37:624-631, 2011
8. Eichler AF, Kahle KT, Wang DL, et al: EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 12:1193-1199, 2010
9. Gow CH, Chien CR, Chang YL, et al: Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 14:162-168, 2008
10. Matsumoto S, Takahashi K, Iwakawa R, et al: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119:1491-1494, 2006 (Pubitemid 44258830)
11. Gazdar AF, Minna JD: Deregulated EGFR signaling during lung cancer progression: Mutations, amplicons, and autocrine loops. Cancer Prev Res (Phila) 1:156-160, 2008
12. Yatabe Y, Matsuo K, Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29:2972-2977, 2011
13. Yatabe Y, Takahashi T, Mitsudomi T: Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFRmutated lung cancer. Cancer Res 68:2106-2111, 2008 (Pubitemid 351521782)
14. Sun M, Behrens C, Feng L, et al: HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15:4829-4837, 2009
15. Hotta K, Kiura K, Ueoka H, et al: Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46:255-261, 2004 (Pubitemid 39330419)
16. Fekrazad MH, Ravindranathan M, Jones DV Jr: Response of intracranial metastases to erlotinib therapy. J Clin Oncol 25:5024-5026, 2007 (Pubitemid 350220437)
17. Gounant V, Wislez M, Poulot V, et al: Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer 58:425-428, 2007 (Pubitemid 350064403)
18. Hata A, Kaji R, Fujita S, et al: High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol 6:653-654, 2011
19. Gridelli C, Bareschino MA, Schettino C, et al: Erlotinib in non-small cell lung cancer treatment: Current status and future development. Oncologist 12:840-849, 2007 (Pubitemid 47328227)